Proposed Decision Memo for Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain (CAG-00429N)

Decision Summary

CMS proposes coverage for Transcutaneous Electrical Nerve Stimulation (TENS) for chronic low back pain (CLBP) only when all of the following conditions are met.

- A. For the purposes of this decision CLBP is defined as:
 - a. an episode of low back pain that has persisted for three months or longer; and
 - b. is not the result of certain well-defined diseases that may contribute to low back pain but which are not primarily low back syndromes.

For example, there are cancers that, through metastatic spread to the spine or pelvis, may elicit pain in the lower back as a symptom. Certain systemic diseases, e.g. rheumatoid arthritis, multiple sclerosis etc, manifest many debilitating symptoms of which low back pain is not the primary focus. We believe that the appropriate management of these types of diseases is guided by a systematic strategy aimed at the underlying causes. While TENS may infrequently be used adjunctively in managing the symptoms of these diseases, it is clearly not the primary therapeutic approach.

- B. The patient is enrolled in a prospective clinical study that addresses one or more aspects of the following questions in a randomized, controlled design using validated and reliable instruments. This can include randomized crossover designs.
 - 1. Does the use of TENS provide a clinically meaningful reduction in pain in Medicare beneficiaries with CLBP?

- 2. Does the use of TENS provide a clinically meaningful improvement of function in Medicare beneficiaries with CLBP?
- 3. Does the use of TENS provide a clinically meaningful reduction in other medical treatments or services used in the medical management of CLBP?

The study must adhere to the following standards of scientific integrity and relevance to the Medicare population:

- a. The principal purpose of the clinical study is to test whether TENS potentially improves the participants' health outcomes.
- b. The clinical study is well supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use.
- c. The clinical study does not unjustifiably duplicate existing studies.
- d. The study design is appropriate to answer the research question being asked in the study.
- e. The clinical study is sponsored by an organization or individual capable of successfully executing the proposed study.
- f. The clinical study is in compliance with all applicable Federal regulations concerning the protection of human subjects found at 45 CFR Part 46.
- g. All aspects of the clinical study are conducted according to appropriate standards of scientific integrity (see http://www.icmje.org).
- h. The clinical study has a written protocol that clearly addresses, or incorporates by reference, the standards listed here as Medicare requirements for CED coverage.
- i. The clinical study is not designed to exclusively test toxicity or disease pathophysiology in healthy individuals.
- j. The clinical study is registered on the ClinicalTrials.gov website by the principal sponsor/investigator prior to the enrollment of the first study subject.
- k. The clinical study protocol specifies the method and timing of public release of all prespecified outcomes to be measured including release of outcomes if outcomes are negative or study is terminated early. The results must be made public within 24 months of the end of data collection. If a report is planned to be published in a peer reviewed journal, then that initial release may be an abstract that meets the requirements of the International Committee of Medical Journal Editors

(http://www. icmje.org). However a full report of the outcomes must be made public no later than three (3) years after the end of data collection.

- I. The clinical study protocol must explicitly discuss subpopulations affected by the treatment under investigation, particularly traditionally underrepresented groups in clinical studies, how the inclusion and exclusion criteria affect enrollment of these populations, and a plan for the retention and reporting of said populations on the trial. If the inclusion and exclusion criteria are expected to have a negative effect on the recruitment or retention of underrepresented populations, the protocol must discuss why these criteria are necessary.
- m. The clinical study protocol explicitly discusses how the results are or are not expected to be generalizable to the Medicare population to infer whether Medicare patients may benefit from the intervention. Separate discussions in the protocol may be necessary for populations eligible for Medicare due to age, disability or Medicaid eligibility.

Consistent with section 1142 of the Social Security Act, AHRQ supports clinical research studies that CMS determines meet the above-listed standards and address the above-listed research questions.

We are requesting public comments to this proposed decision pursuant to section 1862(I) of the Social Security Act (the Act). After consideration of the public comments and any additional evidence, we will issue a final determination responding to the public comments consistent with §1862(I)(3) of the Act.

Back to Top

Proposed Decision Memo

CMS proposes coverage for Transcutaneous Electrical Nerve Stimulation (TENS) for chronic low back pain (CLBP) only when all of the following conditions are met.

- A. For the purposes of this decision CLBP is defined as:
- a. an episode of low back pain that has persisted for three months or longer; and

b. is not the result of certain well-defined diseases that may contribute to low back pain but which are not primarily low back syndromes.

For example, there are cancers that, through metastatic spread to the spine or pelvis, may elicit pain in the lower back as a symptom. Certain systemic diseases, e.g. rheumatoid arthritis, multiple sclerosis etc, manifest many debilitating symptoms of which low back pain is not the primary focus. We believe that the appropriate management of these types of diseases is guided by a systematic strategy aimed at the underlying causes. While TENS may infrequently be used adjunctively in managing the symptoms of these diseases, it is clearly not the primary therapeutic approach.

- B. The patient is enrolled in a prospective clinical study that addresses one or more aspects of the following questions in a randomized, controlled design using validated and reliable instruments. This can include randomized crossover designs.
 - 1. Does the use of TENS provide a clinically meaningful reduction in pain in Medicare beneficiaries with CLBP?
 - 2. Does the use of TENS provide a clinically meaningful improvement of function in Medicare beneficiaries with CLBP?
 - 3. Does the use of TENS provide a clinically meaningful reduction in other medical treatments or services used in the medical management of CLBP?

The study must adhere to the following standards of scientific integrity and relevance to the Medicare population:

- a. The principal purpose of the clinical study is to test whether TENS potentially improves the participants' health outcomes.
- b. The clinical study is well supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use.
- c. The clinical study does not unjustifiably duplicate existing studies.
- d. The study design is appropriate to answer the research question being asked in the study.
- e. The clinical study is sponsored by an organization or individual capable of successfully executing the proposed study.

- f. The clinical study is in compliance with all applicable Federal regulations concerning the protection of human subjects found at 45 CFR Part 46.
- g. All aspects of the clinical study are conducted according to appropriate standards of scientific integrity (see http://www.icmje.org).
- h. The clinical study has a written protocol that clearly addresses, or incorporates by reference, the standards listed here as Medicare requirements for CED coverage.
- i. The clinical study is not designed to exclusively test toxicity or disease pathophysiology in healthy individuals.
- j. The clinical study is registered on the ClinicalTrials.gov website by the principal sponsor/investigator prior to the enrollment of the first study subject.
- k. The clinical study protocol specifies the method and timing of public release of all prespecified outcomes to be measured including release of outcomes if outcomes are negative or study is terminated early. The results must be made public within 24 months of the end of data collection. If a report is planned to be published in a peer reviewed journal, then that initial release may be an abstract that meets the requirements of the International Committee of Medical Journal Editors

(http://www. icmje.org). However a full report of the outcomes must be made public no later than three (3) years after the end of data collection.

- I. The clinical study protocol must explicitly discuss subpopulations affected by the treatment under investigation, particularly traditionally underrepresented groups in clinical studies, how the inclusion and exclusion criteria affect enrollment of these populations, and a plan for the retention and reporting of said populations on the trial. If the inclusion and exclusion criteria are expected to have a negative effect on the recruitment or retention of underrepresented populations, the protocol must discuss why these criteria are necessary.
- m. The clinical study protocol explicitly discusses how the results are or are not expected to be generalizable to the Medicare population to infer whether Medicare patients may benefit from the intervention. Separate discussions in the protocol may be necessary for populations eligible for Medicare due to age, disability or Medicaid eligibility.

Consistent with section 1142 of the Social Security Act, AHRQ supports clinical research studies that CMS determines meet the above-listed standards and address the above-listed research questions.

We are requesting public comments to this proposed decision pursuant to section 1862(I) of the Social Security Act (the Act). After consideration of the public comments and any additional evidence, we will issue a final determination responding to the public comments consistent with §1862(I)(3) of the Act.

Bibliography

Akl E, Briel M, You J, Lamontagne F, Gangj A, Cukierman-Yaffe T, Alshurafa M, Sun X, Nerenberg K, Johnston B, Vera C, Mills E, Bassler D, Salazar A, Bhatnagar N, Busse J, Khalid Z, Walter S, Cook D, Schunemann H, Altman D, Guyatt g. LOST to follow-up Information in Trials (LOST – IT): a protocol on the potential impact. *Trials*. 2009, 10:40.


American Medical Directors Association (AMDA). Pain management in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA). 2009:48.


American Pain Society. Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain: Evidence Review. Glenview, IL: American Pain Society. 2009.

Barker K, Elliot C, Sackley C, Fairbank J. Treatment of chronic back pain by sensory discrimination training. A Phase I RCT of a novel device (FairMed) vs. TENS. *BCM Musculoskeletal Disorders*. 2008;9:97.

Bennett M, Hughes N., and Johnson M. Methodological quality in randomised controlled trials of transcutaneous electric nerve stimulation for pain: Low fidelity may explain negative findings. *Pain*, 2011;152:1226-1232.

Bjordal J. Time for a paradigm shift in pain treatment: Reassessing transcutaneous electrical nerve stimulation (TENS). *Pain. 2011;* 152: 1213-1214.





Chou R, Huffman L. Nonpharmacologic Therapies for Acute and Chronic Low Back pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline. *Annals of Internal Medicine*. 2007;147:492-504.

Chou R, Shekelle P. Will this Patient Develop Persistent Disabling Low Back Pain? *Journal of the American Medical Association*. 2010; 303(13):1295-1302.

Cochrane Collaboration open learning material: Further issues in meta-analysis, Intention to treat issues. Retrieved January 11, 2012 from http://www.cochrane-net.org/openlearning/HTML/mod14-4.htm.

Davidhizar R., Giger J. A review of the literature on care of clients in pain who are culturally diverse. *International Nursing Review.* 2004;51:47-55.

DeSantana J, Sluka K. Central mechanisms in the maintenance of chronic widespread noninflammatory muscle pain. *Current Pain and Headache Reports*. 2008;12:338-343.

DeSantana J, Walsh D, Vance C, Rakel B, Sluka K. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. *Current Rheumatology Reports*. 2008;10:492-499.

Deyo R, Walsh N, Martin D, Schoenfeld L, Ramamurthy S. A Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) and Exercise for Chronic Low Back Pain. *New England Journal of Medicine*. 1990;322(23):1627-1634.


Deyo R, Walsh N, Martin D, Schoenfeld L, Ramamurthy S. Can Trials of Physical Treatments Be Blinded? The Example of Transcutaneous Electrical Nerve Stimulation for Chronic Pain. *American Journal of Physical Medicine & Rehabilitation*. 1990;69(1):6-10.


Dubinsky R, Miyasaki J. Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2010;74:173-176.


Elkiss M, Ingall J, Dooley J. Pilot study on the effects of transcutaneous electrical nerve stimulation on the level of plasma beta-endorphin. *Journal of the American Osteopathic Association*. 1984;84(suppl. 1):144-147.


Fishbain D, Chabal C, Abbott A., Heine L, Cutler R. Transcutaneous Electrical Nerve Stimulation (TENS). Clinical Journal of Pain. 1996;12(3):201-14.


Flowerdew M, Gadsby J. A review of the treatment of chronic low back pain with acupuncture-like transcutaneous electrical nerve stimulation and transcutaneous electrical nerve stimulation. *Complementary Therapies in Medicine*. 1995;5:193-201.












Melzak R, Vetere P, Finch L. Transcutaneous Electrical Nerve Stimulation for Low Back Pain. A Comparison of TENS and Massage for Pain and Range of Motion. *Physical*


Milne S, Welch V, Brosseau L, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous


electrical nerve stimulation (TENS) for chronic low-back pain. *The Cochrane Database of Systematic Reviews*, Issue. Art. No. :CD003008. DOI: 10. 1002/14651858. CD003008.

Therapy. 1983;63(4);489-493.










van Middelkoop M, Rubinstein S, Kuijpers T, Verhagen A, Ostelo R, Koes B, van Tulder M. A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. *European Spine Journal*. 2011;20:19-39.

van Tulder M, Gherkin D, Berman B, Lao L, Koes B. The Effectiveness of Acupuncture in the Management of Acute and Chronic Low Back Pain: A Systematic Review Within the Framework of the Cochrane Collaboration Back Review Group. *Spine*. 1999;24(11):1113-1123.

van Tulder M, Gherkin D, Berman B, Lao L, Koes B. Acupuncture for low-back pain. The *Cochrane Database of Systematic Reviews*, Issue. Art. No.:CD001351. DOI: 10. 1001/14651858. CD001351.

Walsh N, Santa Maria D, Eckmann M. Treatment of the Patient with Chronic Pain in Physical Medicine and Rehabilitation Principles and Practice [Frontera WR, editor in chief]. Wolters Kluwer/Lippincott Williams and Wilkins. 2010.

Warke K, Al-Smadi J, Baxter D, Walsh D, Lowe-Strong A. Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low-back Pain in a Multiple Sclerosis Population. A Randomized, Placebo-controlled Clinical Trial. *Clinical Journal Pain*. 2006;22(9):812-819.



blind, clinical study. Osteoporosis International. 2007;18(11):1541-5.

Zambito A, Bianchini D, Gatti D, Viapiana O, Rossini M, Adami S. Inferential and horizontal therapies in chronic low back pain: a randomized, double blind, clinical study. *Clinical and Experimental Rheumatology*. 2006;24(5):534-9.

Back to Top